1224640-13-4

Basic information

• Product Name: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline
• Synonyms: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline
• CAS NO: 1224640-13-4
• Molecular Formula: C₁₁H₁₄N₂
• Molecular Weight: 174.24226
• Mol File: 1224640-13-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline(1224640-13-4)
• EPA Substance Registry System: 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline(1224640-13-4)

Safety Data

• Hazardous Substances Data: 1224640-13-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-Cyclopropyl-1,2,3,4-tetrahydroquinoxaline is used as a reactant and reagent in organic synthesis for its ability to participate in a wide range of chemical reactions. Its unique structure allows it to be a versatile building block for the creation of more complex organic molecules.
Used in Pharmaceutical Industry:
1-Cyclopropyl-1,2,3,4-tetrahydroquinoxaline is used as an intermediate in the synthesis of various pharmaceutical compounds. Its reactivity and structural diversity make it a valuable component in the development of new drugs with potential therapeutic applications.
Used in Chemical Research:
1-Cyclopropyl-1,2,3,4-tetrahydroquinoxaline is also used in chemical research as a model compound to study the properties and reactivity of cyclopropyl and quinoxaline-containing molecules. This helps researchers understand the behavior of these structures and develop new synthetic strategies and applications.

Upstream product

• 1224640-12-3 1-cyclopropyl-1,2,3,4-tetrahydroquinoxaline-2,3-dione 
• 55432-23-0 cyclopropyl-(2-nitro-phenyl)-amine 
• 1493-27-2 ortho-nitrofluorobenzene 
• 1224640-11-2 1-cyclopropyl-4-hydroxy-1,2,3,4-tetrahydroquinoxaline-2,3-dione 
• 1224640-10-1 N-cyclopropyl-N-(2-nitro-phenyl)-oxalamic acid methyl ester 

Downstream Products

• 1224639-33-1 (4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-[2-(2,5-dichloro-phenoxy)-pyridin-3-yl]-methanone 
• 1224639-71-7 [2-(4-bromo-2,5-dichloro-phenoxy)-pyridin-3-yl]-(4-cyclopropyl-3,4-dihydro-2Hquinoxalin-1-yl)-methanone 
• 1315468-81-5 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoic acid methyl ester 
• 1315468-83-7 4-chloro-5-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-phthalic acid dimethyl ester 
• 1315468-84-8 {2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-acetic acid methyl ester 
• 1315468-85-9 {2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-acetic acid 
• 1315468-88-2 3-{2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-propionic acid ethyl ester 
• 1315468-89-3 3-{2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-propionic acid 
• 1315468-90-6 2-{2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzoylamino}-ethanesulfonic acid 
• 1315468-93-9 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-N-(1 H-tetrazol-5-yl)-benzamide 
• 1315469-13-6 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzamide 
• 1315469-16-9 (4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-[4-(2,5-dichloro-4-hydroxymethyl-phenoxy)-pyridin-3-yl]-methanone 
• 1315469-17-0 2,5-dichloro-4-[3-(4-cyclopropyl-3,4-dihydro-2H-quinoxaline-1-carbonyl)-pyridin-4-yloxy]-benzonitrile 
• 1315469-18-1 (4-cyclopropyl-3,4-dihydro-2H-quinoxalin-1-yl)-[4-(2,5-dichloro-4-hydroxy-phenoxy)-pyridin-3-yl]-methanone 

Relevant articles and documents

Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists

TGR5 is emerging as an important and promising target for the treatment of non-alcoholic steatohepatitis, type 2 diabetes mellitus (T2DM), and obesity. A series of novel 3-phenoxypyrazine-2-carboxamide derivatives were designed, synthesized and evaluated

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

TGR5 is emerging as an important and promising target for the treatment of diabetes, obesity and other metabolic syndromes. A series of novel 1-benzyl-1H-imidazole-5-carboxamide derivatives was designed, synthesized and evaluated in vitro and in vivo. The

2-Phenoxy-nicotinamides are Potent Agonists at the Bile Acid Receptor GPBAR1 (TGR5)

Potency with potential: 2-Phenoxy- nicotinamides were identified as potent agonists at the GPBAR1 receptor, a target in the treatment of obesity, type2 diabetes and metabolic syndrome. Extensive structure-activity relationship studies supported by homolog

NON-SYSTEMIC TGR5 AGONISTS

Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.

4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula (I), wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.

NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula wherein A1, A2, B1, B2 and R1 to R11 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes.